These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 11836805

  • 41. Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis.
    Smyth A, Knox A.
    J Cyst Fibros; 2011 Sep; 10(5):383. PubMed ID: 21507733
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. [Examination of stability and compatibility of flucloxacillin (Floxapen) and ceftazidime (Fortum) in two infusion media: relevance for the clinical praxis].
    Thalhammer F, Maier-Salamon A, Jäger W.
    Wien Med Wochenschr; 2005 Jul; 155(13-14):337-43. PubMed ID: 16092041
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis with high or conventional doses of ceftazidime.
    De Boeck K, Breysem L.
    J Antimicrob Chemother; 1998 Mar; 41(3):407-9. PubMed ID: 9578170
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
    Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL.
    Chest; 2003 May; 123(5):1495-502. PubMed ID: 12740266
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Antipseudomonal antibiotics and cystic fibrosis.
    Henry RL.
    Aust N Z J Med; 1999 Feb; 29(1):5-7. PubMed ID: 10200806
    [No Abstract] [Full Text] [Related]

  • 52. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO.
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
    Padoan R, Brienza A, Crossignani RM, Lodi G, Giunta A, Assael BM, Granata F, Passarella E, Vallaperta PA, Xerri L.
    J Pediatr; 1983 Aug; 103(2):320-4. PubMed ID: 6348228
    [Abstract] [Full Text] [Related]

  • 56. Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Stenvang Pedersen S, Pressler T, Pedersen M, Høiby N, Friis-Møller A, Koch C.
    Scand J Infect Dis; 1986 Aug; 18(2):133-7. PubMed ID: 3518048
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. [Intravenous administration of antibiotics in the treatment of cystic fibrosis].
    Vávrová V, Lochmann O, Suková B, Copová M, Zapletal A, Absolonová V, Houstĕk J.
    Cesk Pediatr; 1986 Oct; 41(10):605-7. PubMed ID: 3502950
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.